Ellevest Inc’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Ellevest Inc’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-32	Closed	–	–	1695
2021 Q4	$0	Buy	32 +20	+167%	+$95	﹤0.01%	1717
2021 Q3	$0	Buy	+12	New	+$66	﹤0.01%	1631

Other funds holding PRTK

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Ellevest Inc's PRTK Position: Q1 2022 in Review

Ellevest Inc sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2022, closing a stake of 32 shares.

Ellevest Inc first reported a position in PRTK in Q3 2021 and held it in 2 quarters. The position peaked at $0 in Q4 2021. 100 funds tracked by Wall St. Rank hold PRTK as of Q1 2022.

Ellevest Inc reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Ellevest Inc sold 32 Paratek Pharmaceuticals, Inc. shares in Q1 2022.
Ellevest Inc first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2021 and held it in 2 quarters.
Ellevest Inc's Paratek Pharmaceuticals, Inc. position peaked at $0 in Q4 2021.
100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2022.

Based on Ellevest Inc's 13F filing for Q1 2022, filed 19 Apr 2022.